{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:15:41Z","timestamp":1789773341157,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.09.010","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T16:34:13Z","timestamp":1505925253000},"page":"825-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients"],"prefix":"10.1016","volume":"17","author":[{"given":"Scott","family":"Ely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsane","family":"Ouansafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1195-1368","authenticated-orcid":false,"given":"Alvin","family":"Modin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Pekle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-825X","authenticated-orcid":false,"given":"David","family":"Jayabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Liberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.09.010_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2017.09.010_bib3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.09.010_bib4","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A\u00a0novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.09.010_bib5","doi-asserted-by":"crossref","first-page":"11345","DOI":"10.1158\/0008-5472.CAN-05-2159","article-title":"Mutually exclusive cyclin-dependent kinase 4\/cyclin D1 and cyclin-dependent kinase 6\/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma","volume":"65","author":"Ely","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.09.010_bib6","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3K\u03b4 inhibition through PIK3IP1","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2017.09.010_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G1 arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle\u2013coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2017.09.010_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.010_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.010_bib11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib12","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","article-title":"Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"56","author":"Niesvizky","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.010_bib13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ajh.24687","article-title":"A\u00a0phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma","volume":"92","author":"Berenson","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.22237","article-title":"Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management","volume":"87","author":"Rajkumar","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.23390","article-title":"Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Rajkumar","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ajh.23810","article-title":"Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management","volume":"89","author":"Rajkumar","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bjh.13620","article-title":"Time to redefine myeloma","volume":"171","author":"Pratt","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.09.010_bib19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.010_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","article-title":"Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"114","author":"Kapoor","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib22","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.09.010_bib23","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","article-title":"Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?","volume":"126","author":"Chretien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib24","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","article-title":"Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience","volume":"125","author":"Hebraud","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr Jens","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2017.09.010_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.09.010_bib27","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2017.09.010_bib28","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2017.09.010_bib29","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib31","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-15-2793","article-title":"Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.09.010_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2016.08.005","article-title":"NF-\u03baB dysregulation in multiple myeloma","volume":"39","author":"Matthews","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2017.09.010_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm0315-204","article-title":"Insurance companies are slow to cover next-generation sequencing","volume":"21","author":"Chakradhar","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2017.09.010_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.seminoncol.2013.08.002","article-title":"Evolving strategies in the initial treatment of multiple myeloma","volume":"40","author":"Rosenbaum","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/1097-0142(20000715)89:2<445::AID-CNCR33>3.0.CO;2-T","article-title":"Telomerase activity in B-cell non-Hodgkin lymphoma","volume":"89","author":"Ely","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.010_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.09.010_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.breast.2008.02.002","article-title":"Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients","volume":"17","author":"Stuart-Harris","year":"2008","journal-title":"Breast"},{"key":"10.1016\/j.clml.2017.09.010_bib38","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000324206","article-title":"High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab","volume":"126","author":"Gaudio","year":"2011","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2017.09.010_bib41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/modpathol.2014.156","article-title":"Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies","volume":"28","author":"Reid","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2017.09.010_bib42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.21406","article-title":"Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma","volume":"84","author":"Broyde","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib44","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0025-6196(12)65066-6","article-title":"Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies","volume":"62","author":"Greipp","year":"1987","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2017.09.010_bib45","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib46","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood.V97.8.2522","article-title":"A\u00a0high bone marrow plasma cell labeling index in stable plateau phase multiple myeloma is a marker for early disease progression and death","volume":"97","author":"Steensma","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib47","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2011-03-341933","article-title":"Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival","volume":"118","author":"Larsen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib48","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/leu.2011.54","article-title":"Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.09.010_bib49","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ijc.20491","article-title":"Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients","volume":"112","author":"Garc\u00eda-Sanz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2017.09.010_bib50","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199909050956","article-title":"The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma","volume":"34","author":"Rimsza","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.010_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.coc.0000045810.91816.41","article-title":"Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma","volume":"27","author":"Alexandrakis","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib53","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-10-1820","article-title":"MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of bax and maintenance of survivin","volume":"17","author":"Nardiello","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.09.010_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer\u2013testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib55","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.09.010_bib56","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib57","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A\u00a0clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.010_bib58","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib59","doi-asserted-by":"crossref","first-page":"908","DOI":"10.6004\/jnccn.2009.0061","article-title":"NCCN clinical practice guidelines in oncology: multiple myeloma","volume":"7","author":"Anderson","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2017.09.010_bib60","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines, 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2017.09.010_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.09.010_bib62","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib63","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib64","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","article-title":"Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)","volume":"102","author":"Touzeau","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.09.010_bib65","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib66","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib67","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00277-016-2692-0","article-title":"Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and\/or t(4;14) and overcomes their adverse prognosis","volume":"95","author":"El-Ghammaz","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib68","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib69","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1200\/JCO.2006.07.1209","article-title":"Ki-67 correlates with in\u00a0vivo bromodeoxyuridine labeling index in operable breast cancer","volume":"24","author":"Goodson","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.24352","article-title":"Reduction in C-reactive protein indicates successful targeting of the IL-1\/IL-6 axis resulting in improved survival in early stage multiple myeloma","volume":"91","author":"Lust","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.24131","article-title":"Outcomes of primary refractory multiple myeloma and the impact of novel therapies","volume":"90","author":"Majithia","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.010_bib72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4065\/mcp.2009.0653","article-title":"Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma","volume":"85","author":"Madan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2017.09.010_bib73","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ejcb.2009.06.005","article-title":"Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan\u2122 assays","volume":"88","author":"Gasparri","year":"2009","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.clml.2017.09.010_bib74","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.010_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2017.09.010_bib76","first-page":"867","article-title":"Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67","volume":"138","author":"Gerdes","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2017.09.010_bib77","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.010_bib79","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:44Z","timestamp":1761870644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017308807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017308807"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}